Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study.

García-Muñoz R, Quero C, Pérez-Persona E, Domingo-García A, Pérez-López C, Villaescusa-de-la-Rosa T, Martínez-Castro AM, Arguiñano-Pérez JM, Parra-Cuadrado JF, Panizo C.

Br J Haematol. 2019 Oct 1. doi: 10.1111/bjh.16227. [Epub ahead of print]

PMID:
31573078
2.

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Jain P, Frigault MM, Izumi R, Nguyen D, Patel P, Yin M, Długosz-Danecka M.

Leukemia. 2019 Sep 26. doi: 10.1038/s41375-019-0575-9. [Epub ahead of print] No abstract available.

PMID:
31558766
3.

PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.

Pascual M, Mena-Varas M, Robles EF, Garcia-Barchino MJ, Panizo C, Hervas-Stubbs S, Alignani D, Sagardoy A, Martinez-Ferrandis JI, Bunting KL, Meier S, Sagaert X, Bagnara D, Guruceaga E, Blanco O, Celay J, Martínez-Baztan A, Casares N, Lasarte JJ, MacCarthy T, Melnick A, Martinez-Climent JA, Roa S.

Blood. 2019 May 30;133(22):2401-2412. doi: 10.1182/blood.2018889931. Epub 2019 Apr 11.

PMID:
30975638
4.

Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma.

Gonzalez-Farre B, Ramis-Zaldivar JE, Salmeron-Villalobos J, Balagué O, Celis V, Verdu-Amoros J, Nadeu F, Sábado C, Ferrández A, Garrido M, García-Bragado F, de la Maya MD, Vagace JM, Panizo CM, Astigarraga I, Andrés M, Jaffe ES, Campo E, Salaverria I.

Haematologica. 2019 Sep;104(9):1822-1829. doi: 10.3324/haematol.2018.207928. Epub 2019 Feb 7.

5.

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.

Moreno L, Perez C, Zabaleta A, Manrique I, Alignani D, Ajona D, Blanco L, Lasa M, Maiso P, Rodriguez I, Garate S, Jelinek T, Segura V, Moreno C, Merino J, Rodriguez-Otero P, Panizo C, Prosper F, San-Miguel JF, Paiva B.

Clin Cancer Res. 2019 May 15;25(10):3176-3187. doi: 10.1158/1078-0432.CCR-18-1597. Epub 2019 Jan 28.

PMID:
30692097
6.

Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma.

González-Barca E, Coronado M, Martín A, Montalbán C, Montes-Moreno S, Panizo C, Rodríguez G, Sancho JM, López-Hernández A; Spanish Lymphoma Group (GELTAMO).

Oncotarget. 2018 Aug 17;9(64):32383-32399. doi: 10.18632/oncotarget.25892. eCollection 2018 Aug 17. Review.

7.

Update on posttransplant lymphoproliferative disease.

Martin-Moreno PL, Panizo C.

Curr Opin Nephrol Hypertens. 2018 Nov;27(6):440-444. doi: 10.1097/MNH.0000000000000457. Review.

PMID:
30157079
8.

A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.

de Jong J, Hellemans P, De Wilde S, Patricia D, Masterson T, Manikhas G, Myasnikov A, Osmanov D, Córdoba R, Panizo C, de Zwart L, Snoeys J, Chauhan V, Jiao J, Sukbuntherng J, Ouellet D.

Leuk Lymphoma. 2018 Dec;59(12):2888-2895. doi: 10.1080/10428194.2018.1460474. Epub 2018 May 30.

PMID:
29846137
9.

Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia.

García-Muñoz R, Aguinaga L, Feliu J, Anton-Remirez J, Jorge-Del-Val L, Casajús-Navasal A, Nebot-Villacampa MJ, Daroca-Fernandez I, Domínguez-Garrido E, Rabasa P, Panizo C.

Immunotherapy. 2018 Mar 1;10(6):491-499. doi: 10.2217/imt-2017-0147.

PMID:
29562857
10.

Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.

García-Barchino MJ, Sarasquete ME, Panizo C, Morscio J, Martinez A, Alcoceba M, Fresquet V, Gonzalez-Farre B, Paiva B, Young KH, Robles EF, Roa S, Celay J, Larrayoz M, Rossi D, Gaidano G, Montes-Moreno S, Piris MA, Balanzategui A, Jimenez C, Rodriguez I, Calasanz MJ, Larrayoz MJ, Segura V, Garcia-Muñoz R, Rabasa MP, Yi S, Li J, Zhang M, Xu-Monette ZY, Puig-Moron N, Orfao A, Böttcher S, Hernandez-Rivas JM, Miguel JS, Prosper F, Tousseyn T, Sagaert X, Gonzalez M, Martinez-Climent JA.

J Pathol. 2018 May;245(1):61-73. doi: 10.1002/path.5060. Epub 2018 Mar 30.

PMID:
29464716
11.

Post-transplant lymphoproliferative disease after liver transplantation.

Herrero JI, Panizo C.

Rev Esp Enferm Dig. 2018 Feb;110(2):131-132. doi: 10.17235/reed.2017.5387/2017.

12.

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W.

Lancet. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11.

PMID:
29241979
13.

Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms.

Celay J, Lozano T, Concepcion AR, Beltrán E, Rudilla F, García-Barchino MJ, Robles EF, Rabal O, de Miguel I, Panizo C, Casares N, Oyarzabal J, Prieto J, Medina JF, Lasarte JJ, Martínez-Climent JÁ.

Haematologica. 2018 Jun;103(6):1065-1072. doi: 10.3324/haematol.2017.175687. Epub 2017 Nov 30.

14.

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.

Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver J, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C.

Blood. 2017 Oct 12;130(15):1772-1774. doi: 10.1182/blood-2017-07-795302. Epub 2017 Aug 11. No abstract available.

PMID:
28801448
15.

Common variable immunodeficiency-associated granulomatous and lymphocytic interstitial lung disease successfully treated with a combination regimen of rituximab and azathioprine.

Moctezuma SI, Panizo CM, Landecho MF.

Med Clin (Barc). 2017 Oct 11;149(7):312-313. doi: 10.1016/j.medcli.2017.05.041. Epub 2017 Jul 21. English, Spanish. No abstract available.

PMID:
28736065
16.

Obinutuzumab in follicular lymphoma.

Martinez-Calle N, Figueroa-Mora R, Villar-Fernandez S, Marcos-Jubilar M, Panizo C.

Drugs Today (Barc). 2016 Dec;52(12):643-651. doi: 10.1358/dot.2016.52.12.2550578. Review.

PMID:
28276536
17.

Clinical management, expectations, and satisfaction of patients with moderate to severe allergic rhinoconjunctivitis treated with SQ-standardized grass-allergen tablet under routine clinical practice conditions in Spain.

Chivato T, Álvarez-Calderón P, Panizo C, Abengozar R, Alías C, Al-Baech A, Arias-Irigoyen J, Caballero MJ, Conill L, de Miguel S, Laguna R, Martínez-Benazet J, Matoses F, Martínez-Alonso JC, Mendizábal L, Pérez-Carral C, Puerto C, Serra-Batllés J, Vélez A, Vicente J, de la Torre F.

Clin Mol Allergy. 2017 Jan 6;15:1. doi: 10.1186/s12948-016-0057-9. eCollection 2017.

18.

A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates.

Delgado JA, Guillén-Grima F, Moreno C, Panizo C, Pérez-Robles C, Mata JJ, Moreno L, Arana P, Chocarro S, Merino J.

J Immunol Methods. 2017 Mar;442:54-58. doi: 10.1016/j.jim.2016.12.006. Epub 2016 Dec 29.

PMID:
28041941
19.

Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).

Peñalver FJ, Sancho JM, de la Fuente A, Olave MT, Martín A, Panizo C, Pérez E, Salar A, Orfao A; Spanish Lymphoma Group (GELTAMO).

Haematologica. 2017 Feb;102(2):235-245. doi: 10.3324/haematol.2016.149120. Epub 2016 Oct 20.

20.

Follicular lymphoma (FL): Immunological tolerance theory in FL.

García-Muñoz R, Panizo C.

Hum Immunol. 2017 Feb;78(2):138-145. doi: 10.1016/j.humimm.2016.09.010. Epub 2016 Sep 30. Review.

PMID:
27693433
21.

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.

Robles EF, Mena-Varas M, Barrio L, Merino-Cortes SV, Balogh P, Du MQ, Akasaka T, Parker A, Roa S, Panizo C, Martin-Guerrero I, Siebert R, Segura V, Agirre X, Macri-Pellizeri L, Aldaz B, Vilas-Zornoza A, Zhang S, Moody S, Calasanz MJ, Tousseyn T, Broccardo C, Brousset P, Campos-Sanchez E, Cobaleda C, Sanchez-Garcia I, Fernandez-Luna JL, Garcia-Muñoz R, Pena E, Bellosillo B, Salar A, Baptista MJ, Hernandez-Rivas JM, Gonzalez M, Terol MJ, Climent J, Ferrandez A, Sagaert X, Melnick AM, Prosper F, Oscier DG, Carrasco YR, Dyer MJ, Martinez-Climent JA.

Nat Commun. 2016 Jun 14;7:11889. doi: 10.1038/ncomms11889.

22.

First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.

Martínez-Calle N, Alfonso A, Rifón J, Herrero I, Errasti P, Rábago G, Merino J, Panizo Á, Pardo J, Prósper F, García-Muñoz R, Lecumberri R, Panizo C.

Eur J Haematol. 2017 Jan;98(1):38-43. doi: 10.1111/ejh.12782. Epub 2016 Jun 28.

PMID:
27232286
23.

Nasal Hyperreactivity: Nonspecific Nasal Provocation Tests. Review by the Rhinoconjunctivitis Committee of the Spanish Society of Allergy and Clinical Immunology.

Lluch-Bernal M, Dordal MT, Antón E, Campo P, Colás C, Dávila I, Del Cuvillo Bernal A, Fernández-Parra B, González R, González ML, Matheu V, Montoro J, Panizo C, Rondón C, Sánchez MC, Valero A, Vega F, Velázquez E, Navarro A; SEAIC 2010 Rhinoconjunctivitis Committee.

J Investig Allergol Clin Immunol. 2015;25(6):396-407. Review.

24.

Timothy grass pollen therapeutic vaccine: optimal dose for subcutaneous immunotherapy.

Sola J, da Silva Ferreira JA, Dionicio Elera J, Plácido JL, Pereira C, Fonseca J, Panizo C, Inácio LF, Cancelleire N, Zubeldia Ortuño JM, Landeta A, Madariaga B, Martínez A.

Immunotherapy. 2016;8(3):251-63. doi: 10.2217/imt.15.125. Epub 2016 Jan 13. Erratum in: Immunotherapy. 2017 Jan;9(1):111.

PMID:
26760111
25.

Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.

García-Muñoz R, López-Díaz-de-Cerio A, Feliu J, Panizo A, Giraldo P, Rodríguez-Calvillo M, Grande C, Pena E, Olave M, Panizo C, Inogés S.

Immunol Res. 2016 Apr;64(2):548-57. doi: 10.1007/s12026-015-8747-9.

PMID:
26659089
26.

Relationship between respiratory and food allergy and evaluation of preventive measures.

Vega F, Panizo C, Dordal MT, González ML, Velázquez E, Valero A, Sánchez MC, Rondón C, Montoro J, Matheu V, Lluch-Bernal M, González R, Fernández-Parra B, Del Cuvillo A, Dávila I, Colás C, Campo P, Antón E, Navarro AM; Rhinoconjunctivitis Committee of Spanish Society of Allergology, Clinical Immunology (SEAIC) 2010.

Allergol Immunopathol (Madr). 2016 May-Jun;44(3):263-75. doi: 10.1016/j.aller.2015.05.008. Epub 2015 Aug 25. Review.

PMID:
26316421
27.

Exploratory study of tolerability and immunological effect of a short up-dosing immunotherapy phase with a standardised allergen extract derived from pollen of Olea europaea.

Moreno C, De San Pedro BS, Millán C, Panizo C, Martín S, Florido F.

Clin Transl Allergy. 2015 Jul 24;5:27. doi: 10.1186/s13601-015-0070-y. eCollection 2015.

28.

Consensus document on allergic conjunctivitis (DECA).

Sánchez-Hernández MC, Montero J, Rondon C, Benitez del Castillo JM, Velázquez E, Herreras JM, Fernández-Parra B, Merayo-Lloves J, Del Cuvillo A, Vega F, Valero A, Panizo C, Montoro J, Matheu V, Lluch-Bernal M, González ML, González R, Dordal MT, Dávila I, Colás C, Campo P, Antón E, Navarro A; SEAIC 2010 Rhinoconjunctivitis Committee; Spanish Group Ocular Surface-GESOC.

J Investig Allergol Clin Immunol. 2015;25(2):94-106.

29.

Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.

Panizo C, Rodríguez AJ, Gutiérrez G, Díaz FJ, González-Barca E, de Oña R, Grande C, Sancho JM, García-Álvarez MF, Sánchez-González B, Peñalver FJ, Cannata J, Espeso M, Requena MJ, Gardella S, Durán S, González AP, Alfonso A, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea GELTAMO Spanish Cooperative Group.

Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):398-403. doi: 10.1016/j.clml.2015.02.029. Epub 2015 Mar 5.

PMID:
25843416
30.

First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial.

Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver FJ, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C; Grupo Español de Linfomas/Trasplante de Médula Ósea (GELTAMO).

Lancet Haematol. 2014 Dec;1(3):e104-11. doi: 10.1016/S2352-3026(14)00021-0. Epub 2014 Nov 19.

PMID:
27029228
31.

Long-term prophylaxis with C1-inhibitor concentrate in patients with hereditary angioedema.

Pedrosa M, Lobera T, Panizo C, Jurado J, Caballero T.

J Investig Allergol Clin Immunol. 2014;24(4):271-3. No abstract available.

32.

Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.

Pardal E, Coronado M, Martín A, Grande C, Marín-Niebla A, Panizo C, Bello JL, Conde E, Hernández MT, Arranz R, Bargay J, González-Barca E, Pérez-Ceballos E, Montes-Moreno S, Caballero MD.

Br J Haematol. 2014 Nov;167(3):327-36. doi: 10.1111/bjh.13036. Epub 2014 Jul 28.

PMID:
25066542
33.

Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.

Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D; Grupo Español de Linfomas y Trasplante Autologo de Médula Ósea (GELTAMO).

Haematologica. 2014 Jul;99(7):e126. doi: 10.3324/haematol.2014.108308. No abstract available.

34.

Antidesmocollin 1 autoantibody negative subcorneal pustular dermatosis-type IgA pemphigus associated with multiple myeloma.

España A, Gimenez-Azcarate A, Ishii N, Idoate MA, Panizo C, Hashimoto T.

Br J Dermatol. 2015 Jan;172(1):296-8. doi: 10.1111/bjd.13233. Epub 2014 Dec 8. No abstract available.

PMID:
24980095
35.

Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab.

García Muñoz R, Izquierdo-Gil A, Muñoz A, Roldan-Galiacho V, Rabasa P, Panizo C.

Ann Hematol. 2014 Nov;93(11):1879-87. doi: 10.1007/s00277-014-2135-8. Epub 2014 Jun 21.

PMID:
24951124
36.

Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience.

García-Noblejas A, Martínez Chamorro C, Navarro Matilla B, Da Silva Rodriguez C, González-Lopez TJ, Oña Navarrete R, Ramírez Sánchez MJ, Martínez Barranco P, Sánchez Blanco JJ, Nicolás C, Pérez R, Sánchez González B, Ruedas López AM, Domingo-Domenech E, Panizo C, Macia S, Fernández-Fonseca E, Cannata-Ortiz J, Arranz R.

Ann Hematol. 2014 Sep;93(9):1551-8. doi: 10.1007/s00277-014-2077-1. Epub 2014 Apr 30.

PMID:
24782117
37.

Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.

Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D; GELTAMO.

Haematologica. 2014 Mar;99(3):505-10. doi: 10.3324/haematol.2013.093450. Epub 2013 Oct 25.

38.

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma.

Alcoceba M, Sebastián E, Marín L, Balanzategui A, Sarasquete ME, Chillón MC, Jiménez C, Puig N, Corral R, Pardal E, Grande C, Bello JL, Albo C, de la Cruz F, Panizo C, Martín A, González-Barca E, Caballero MD, San Miguel JF, García-Sanz R, González M.

Blood. 2013 Aug 22;122(8):1448-54. doi: 10.1182/blood-2013-02-483420. Epub 2013 Jul 10.

PMID:
23843497
39.

Rituximab in dermatology.

España A, Ornilla E, Panizo C.

Actas Dermosifiliogr. 2013 Jun;104(5):380-92. doi: 10.1016/j.adengl.2013.04.002. Epub 2013 May 10. Review. English, Spanish.

PMID:
23665436
40.

A new modified prophylactic scheme against liposomal cytarabine-induced arachnoiditis in adult patients with lymphoma.

Sanchez-Gonzalez B, Llorente A, Sancho JM, Panizo C, Guinea JM, Cladera A, Mateos C, Salar A.

Leuk Lymphoma. 2013 Apr;54(4):892-3. doi: 10.3109/10428194.2012.731603. Epub 2012 Oct 8. No abstract available.

PMID:
22988933
41.

Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.

Sanchez-Gonzalez B, Peñalver FJ, Medina A, Guillén H, Calleja M, Gironella M, Arranz R, Sebastian E, de Oña R, Cánovas A, de la Fuente I, Grande C, Sancho JM, Perez R, Domingo E, Lopez-Lorenzo JL, Prieto E, Panizo C, Gorosquieta A, Perez I, Cervera JM, Marin M, Mencha C, Ramila E, Salar A.

Leuk Res. 2012 Jun;36(6):709-14. doi: 10.1016/j.leukres.2011.10.024. Epub 2011 Dec 7.

PMID:
22154023
42.

In vivo and in vitro immunological changes induced by a short course of grass allergy immunotherapy tablets.

Panizo C, Cimarra M, González-Mancebo E, Vega A, Senent C, Martín S.

J Investig Allergol Clin Immunol. 2010;20(6):454-62.

43.

Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma.

Gállego Pérez-Larraya J, Palma JA, Carmona-Iragui M, Fernández-Torrón R, Irimia P, Rodríguez-Otero P, Panizo C, Martínez-Vila E.

J Neurooncol. 2011 Jul;103(3):603-9. doi: 10.1007/s11060-010-0428-x. Epub 2010 Oct 17.

PMID:
20953897
44.

Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.

Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X, Calasanz MJ, Panizo C, Richter JA, Hernandez JM, Roman-Gomez J, Prosper F, Martinez-Climent JA.

Blood. 2010 Oct 7;116(14):2531-42. doi: 10.1182/blood-2010-02-268003. Epub 2010 Jun 22.

45.

Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era.

Sancho JM, Orfao A, Quijano S, García O, Panizo C, Pérez-Ceballos E, Deben G, Salar A, González-Barca E, Alonso N, García-Vela JA, Capote J, Peñalver FJ, Provencio M, Arias J, Plaza J, Caballero D, Morado M, Feliu E, Ribera JM; Spanish Group for the Study of CNS Disease in NHL.

Eur J Haematol. 2010 Oct;85(4):321-8. doi: 10.1111/j.1600-0609.2010.01478.x. Epub 2010 Jul 28.

PMID:
20528905
46.

Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation.

Calvo-Villas JM, Martín A, Conde E, Pascual A, Heras I, Varela R, de la Rubia J, Ramirez MJ, Díez-Martín JL, Panizo C, Rodríguez-Salazar MJ, Pascual MJ, Donato EM, González-Barca E, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO cooperative group).

Ann Oncol. 2010 Sep;21(9):1891-7. doi: 10.1093/annonc/mdq035. Epub 2010 Mar 15.

PMID:
20231299
47.

Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease.

Domingo E, Moreno C, Sánchez-Ibarrola A, Panizo C, Páramo JA, Merino J.

Haematologica. 2010 Apr;95(4):691-2. doi: 10.3324/haematol.2009.018911. Epub 2009 Nov 30. No abstract available.

48.

Primary bone lymphoma of the mandible and thyroid incidentaloma identified by FDG PET/CT: a case report.

Bosch-Barrera J, Arbea L, García-Velloso MJ, Gil-Bazo I, García-Foncillas J, Panizo C.

Cases J. 2009 Jun 26;2:6384. doi: 10.4076/1757-1626-2-6384.

49.

Autoimmunity and lymphoma: is mantle cell lymphoma a mistake of the receptor editing mechanism?

García-Muñoz R, Panizo C, Bendandi M, Llorente L.

Leuk Res. 2009 Nov;33(11):1437-9. doi: 10.1016/j.leukres.2009.05.008. Epub 2009 Jun 11.

PMID:
19523686
50.

[Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide].

España Alonso A, Panizo C, Fernández S, Marquina M, Pretel M, Aguado L, Sánchez-Ibarrola A.

Actas Dermosifiliogr. 2009 Mar;100(2):113-20. Spanish.

PMID:
19445875

Supplemental Content

Loading ...
Support Center